Charles river establishes expdna™ plasmid manufacturing platform to expedite dna programs

Wilmington, mass.--( business wire )--charles river laboratories international, inc. (nyse: crl) today announced the launch of its expdna™ plasmid platform, established from the company's contract development and manufacturing (cdmo) and biologics testing experience. the platform significantly reduces plasmid development and production timelines while streamlining the development journey for cell and gene therapy and vaccine developers with a focus on product quality and consistency.
CRL Ratings Summary
CRL Quant Ranking